Mikhail Blagosklonny is an oncology professor at the Roswell Park cancer institute. He is a scientist whose passion is on the studies of aging and cancer. He attended the first Pavlov Medical University in St. Petersburg from where he attained his MD in internal medicine. He later attained a PhD in experimental medicine and cardiology at the same institution.
In 2002, he was made the associate medical professor in New York medical college in Valhalla. He later moved on to Ordway research institute where he became the lead scientists. His career at Roswell Park cancer institute began in 2009 when he joined as the professor of oncology. He became an excellent professor due to the accumulation of knowledge and the experience he had gathered from all the other places he had worked. View his LinkedIn profile
He has a research interest in bio gerontology, which explains the underlying mechanism of aging. He also focus on anti-aging drugs, targeted cancer therapies that prevent destruction of cells as well as research on cancer in general. He also serves as the chief editor of cell cycle and Oncotarget. He also works as the associate editor for cancer biology and therapy. He also serves in the editorial board of cell death and differentiation editorial board.
Mikhail developed a hypothesis on TOR, which signaled the potential role of cancer as well as aging. He also proposed the use of Rapamycin which is a drug used in the treatment of cancer. His proposal was meant to be used for potential life extension. In fact, he is categorized as a vocal and most passionate researcher when it comes to advocating for the use of rapamycin in life elongation researches. His researches are based on molecular, cellular as well as clinical investigations. As such, it includes tumor suppressors, drug resistance, apoptosis and anticancer therapeutics among others.
The professor also serves as the author of the aging hyper function theory. Mikhail Blagosklonny is also passionate about writing on cyclo therapy and chemotherapeutic engineering. He has especially a very keen interest in oncology and has a strong belief in the possibility of controlling cancer and aging.
Oncotarget is a comprehensive peer review site that publishes oncology journals and any other scientific research from approved scientists. The site currently has thousands of oncology documents and publications from scientific authors comprising scientific works and articles. Most of the journals range from cancer-related research to aging and prevention and recommendations to prevent both.
The site allows other authors to post insightful reviews of the published research giving critics on the formulated hypothesis as well as giving additional tips to make the research findings detailed and worth the purpose. Oncotarget has many professional authors who provide reviews as they seem right according to the professional prerequisites and ethics, and later approve the journal for publication. Oncotarget primary goal is to have a world with no diseases, a goal they work hard to achieve by giving an open platform to the interested professionals in the field of medicine.
To ensure clarity and accuracy of the information in the journals, Oncotarget has a board of editors lead by Dr. Mikhail Blagosklonny who has been in the field for quite some time. With such a chief editor, all journals are critically analyzed and released for publication only when the content pleases the board and the rest of peer reviewers. Since 2010, Oncotarget has published more than 300 articles on oxygen related topics and others that got released by Gregg Semenza who won the 2016 Laker Award for coming up with the discovery of oxygen-sensing pathway.
To allow free flow of ideas and submissions, Oncotarget has made the site to be open access to have a broad platform of readers and professionals contributing to the platform on oncotarget.com. After the journals are approved to be useful, they are stored in the achieve docket on the left column on the platform. Here, the reader access as many journals as he wants to acquire knowledge on the topic in question. Other than oncology, Oncotarget has widened their submission topics to include immunology, geotarget, metabolism, cardiology, Cell & Mol Biology, and Pharmacology.
Oncotarget continually encourages prospect authors to keep submitting their articles for review and publication on scimagojr.com. the approved articles are published weekly by impact journals and alerts are sent to subscribers when the new journal get published. Oncortaget has a broad customer service which is found on facebook, twitter, youtube channel, and linked in. Oncortaget holds strong to its mission of becoming the leading peer review site that work to eradicate all cancer related diseases through provision of adequate research and qualitative findings. See: https://www.dovepress.com/oncotargets-and-therapy-journal